Literature DB >> 15785976

[Optical coherence tomography in Malattia Leventinese].

M-C Gaillard1, T J Wolfensberger, S Uffer, I Mantel, J-A Pournaras, D F Schorderet, F L Munier.   

Abstract

BACKGROUND: Malattia Leventinese (ML) is a genetically homogeneous macular dystrophy with an autosomal dominant mode of inheritance. Ophthalmoscopically it is recognisable by a radial pattern of drusen-like deposits in the macula and by parapapillary deposits, named Forni's verrucosities. The aim of this study is to describe optical coherence tomographic (OCT) findings and to compare them with histological data. PATIENTS AND METHODS: Six patients underwent ophthalmological examination, angiography and OCT. Diagnosis was confirmed by genetic analysis of the R345W mutation. A histopathological study of an ML donor eye was performed.
RESULTS: OCT revealed a diffuse RPE-choriocapillaris thickening with nodular features in the macular and parapapillary areas. The protrusions reached as far as the outer nuclear layer.
CONCLUSIONS: OCT is a non-invasive technique that provides a cross-sectional picture of the retina comparable to a histological section. In ML, OCT revealed a diffuse alteration of the RPE-Bruch's membrane complex. The macular and parapapillary nodular lesions are the tomographic equivalents of drusen and Forni's verrucosities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15785976     DOI: 10.1055/s-2005-857972

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  2 in total

1.  Retinal microstructure in patients with EFEMP1 retinal dystrophy evaluated by Fourier domain OCT.

Authors:  C Gerth; R J Zawadzki; J S Werner; E Héon
Journal:  Eye (Lond)       Date:  2008-09-12       Impact factor: 3.775

2.  A novel haplotype with the R345W mutation in the EFEMP1 gene associated with autosomal dominant drusen in a Japanese family.

Authors:  Tomokazu Takeuchi; Takaaki Hayashi; Matthew Bedell; Kang Zhang; Hisashi Yamada; Hiroshi Tsuneoka
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-22       Impact factor: 4.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.